Form 4: Travere Therapeutics Executive Exercises and Sells Shares Following Positive Regulatory Milestone

William E. Rote, Senior Vice President of R&D at Travere Therapeutics, exercised performance-based restricted stock units (PSUs) and sold a portion of the acquired shares to cover tax obligations after the company confirmed a path forward for traditional approval of FILSPARI.

Summary

• William E. Rote, a Senior Vice President at Travere Therapeutics, exercised performance-based restricted stock units (PSUs) covering 8,000 shares on February 10, 2025.
• The PSUs vested because Travere Therapeutics confirmed a path forward for submitting a supplemental New Drug Application (sNDA) for traditional approval of FILSPARI (sparsentan) in FSGS.
• Following the vesting, Rote sold 5,200 shares of common stock on February 12, 2025, at a price of $23.53 per share.
• The sale was executed under a pre-arranged trading plan (Rule 10b5-1) adopted on March 15, 2024, and included shares sold to cover tax obligations arising from the PSU vesting.
• After the transactions, Rote directly owns 98,519 shares of Travere Therapeutics common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the PSU vesting indicates progress towards regulatory approval for FILSPARI. The stock sale is a routine transaction and doesn't significantly impact the overall sentiment.

Positives

• The vesting of PSUs indicates the achievement of certain clinical/regulatory performance criteria related to FILSPARI.
• Confirmation of a path forward for sNDA submission for FILSPARI suggests positive progress in obtaining traditional approval.
• The use of a 10b5-1 trading plan demonstrates compliance with insider trading regulations.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting of PSUs is tied to future regulatory milestones for FILSPARI.

Industry Context

This filing reflects the standard practice of executives receiving stock-based compensation and managing their holdings. The vesting of PSUs tied to regulatory milestones is common in the pharmaceutical industry, aligning executive incentives with company goals.

Comparison to Industry Standards

• Stock option and RSU grants are a very common form of compensation for executives in publicly traded companies, especially in the biotech and pharmaceutical industries.
• Companies like Amgen, Gilead, and Biogen also use similar performance-based equity compensation to align executive incentives with the achievement of key clinical and regulatory milestones.
• The use of 10b5-1 trading plans is a standard practice to allow insiders to sell shares without concerns about insider trading violations.

Stakeholder Impact

• Shareholders may view the PSU vesting as a positive sign of progress towards regulatory approval for FILSPARI.
• The stock sale by an executive could have a minor impact on the stock price, but is unlikely to be significant given the relatively small volume.

Key Dates

Keywords

Travere Therapeutics, TVTX, William E. Rote, FILSPARI, sparsentan, PSU, sNDA, FSGS, Rule 10b5-1, insider trading, stock sale, executive compensation